FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act, including whether the acquisition of the nonbanking company can ''reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices'' (12 U.S.C. 1843). Any request for a hearing must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than February 7, 1997.

A. Federal Reserve Bank of Atlanta (Zane R. Kelley, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303:

1. Community Bancorp of Louisiana, Inc., Raceland, Louisiana; to merge with American Security Bancshares, Inc., Welsh, Louisiana, and thereby indirectly acquire American Bank, Welsh, Louisiana.

B. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. Damen Financial Corporation, Schaumburg, Illinois; to become a bank holding by acquiring 100 percent of the voting shares of Damen National Bank, Schaumburg, Illinois (in organization).

Board of Governors of the Federal Reserve System, January 7, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–692 Filed 1–10–97; 8:45 am]

BILLING CODE 6210–01–F

GENERAL SERVICES ADMINISTRATION

Information Security Oversight Office; Cancellation of Optional Form

AGENCY: General Services Administration.

ACTION: Notice.

SUMMARY: Because of low usage the following Optional Form is cancelled: OF 95, Opened/Locked Sign for Restricted Files.

DATES: Effective January 13, 1997.

FOR FURTHER INFORMATION CONTACT: Ms. Barbara Williams, General Services Administration, (202) 501–0581.

Dated: December 23, 1996.

Steven Garfinkel,

Director, Information Security Oversight Office.

[FR Doc. 97–713 Filed 1–10–97; 8:45 am]

BILLING CODE 6820–34–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 96D–0300]

Reviewer Guidance for a Premarket Notification Submission for Blood Establishment Computer Software; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a guidance document entitled ''Reviewer Guidance for a Premarket Notification Submission for Blood Establishment Computer Software.'' The guidance document applies to blood establishment software products intended for use in the manufacture of blood and blood components or for the maintenance of data that blood establishment personnel use in making decisions regarding the suitability of donors and the release of blood or blood components for transfusion or further manufacture. The guidance presents an overview of the type of information, including methods and procedures, that FDA's reviewers should expect to be included in 510(k) submissions for such devices and describes the approach FDA's reviewers should take in reviewing premarket submissions for blood establishment computer software.

DATES: Written comments may be submitted at any time, however, to ensure comments are considered for the next revision they should be submitted by April 14, 1997.

ADDRESSES: Submit written comments and information to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857. Submit written requests for single copies of the guidance entitled ''Reviewer Guidance for a Premarket Notification Submission for Blood Establishment Computer Software'' to the Office of Communication, Training, and Manufacturers Assistance (HFM–40), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448. Send one self-addressed adhesive label to assist that office in processing your requests.

The document may also be obtained by calling the CBER Voice Information System at 1–800–835–4709 or 301–827–1800, or FAX at 1–800–CBER–FAX, or 301–827–3844.

Persons with access to the INTERNET may obtain the document using the World Wide Web (WWW), or bounce-back e-mail. For WWW access, connect to CBER at ''http.fda.gov/cber/cberftp.html''. To receive the document by bounce-back e-mail, send a message to ''SWREVIEW@al.cber.fda.gov''.

FOR FURTHER INFORMATION CONTACT: Nancy J. Jensen, Office of Blood Research and Review/Division of Blood Applications, Center for Biologics Evaluation and Research (HFM–385), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–3524.

SUPPLEMENTARY INFORMATION: FDA is announcing the availability of a